Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-09-26 pm EDT
4.660 USD   -4.70%
09/22ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology
CI
09/21ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
BU
09/21JPMorgan Starts ADC Therapeutics at Underweight with $5 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADC Therapeutics : Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial - Form 6-K

07/11/2022 | 07:34am EDT

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

LOTIS-5 is intended to serve as the basis for a supplemental BLA (sBLA) in the U.S. and China in second-line transplant ineligible DLBCL

BOSTON, SHANGHAI and LAUSANNE, Switzerland, July 11, 2022 - Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals ("Overland") and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed in China with ZYNLONTA® in combination with rituximab compared to standard immunochemotherapy in the LOTIS-5 confirmatory Phase 3 global clinical trial in second-line or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL).

In April 2021, ZYNLONTA was granted accelerated approval by the U.S. Food and Drug Administration (FDA) as the first and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. The joint venture has now joined the LOTIS-5 global confirmatory Phase 3 clinical trial of ZYNLONTA, which is intended to support a supplemental Biologics License Application (sBLA) for ZYNLONTA in the U.S. and China in second-line, transplant-ineligible patients.


ZYNLONTA, Overland ADCT BioPharma's lead product candidate, is an ADC composed of a humanized monoclonal antibody directed against human CD19 and conjugated to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. In clinical trials, ZYNLONTA has demonstrated significant single-agent clinical activity across a broad population of patients with r/r DLBCL, mantle cell lymphoma and follicular lymphoma.

About ZYNLONTA® (loncastuximab tesirine-lpyl)

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

About Overland ADCT BioPharma


Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics, is developing four of ADC Therapeutics' antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors - loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 - in greater China and Singapore.

About ADC Therapeutics


ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

About Overland Pharmaceuticals


Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world. By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas. Through formative partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.

ADC Therapeutics Forward-Looking Statements


This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business and commercial strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

INCORPORATION BY REFERENCE

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-256686 and 333-256807) of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Disclaimer

ADC Therapeutics SA published this content on 11 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2022 11:33:09 UTC.


© Publicnow 2022
All news about ADC THERAPEUTICS SA
09/22ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of ..
CI
09/21ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the..
BU
09/21JPMorgan Starts ADC Therapeutics at Underweight with $5 Price Target
MT
09/19HC Wainwright Adjusts ADC Therapeutics' Price Target to $21 From $20, Maintains Buy Rat..
MT
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractor..
MT
09/16Swedish Orphan Biovitrum, ADC Therapeutics Win Recommendation For Lymphoma Medication
MT
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
CI
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
BU
09/16ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Autho..
DJ
09/13Transcript : ADC Therapeutics SA Presents at Morgan Stanley 20th Annual Globa..
CI
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 176 M - -
Net income 2022 -165 M - -
Net cash 2022 317 M - -
P/E ratio 2022 -2,21x
Yield 2022 -
Capitalization 372 M 372 M -
EV / Sales 2022 0,31x
EV / Sales 2023 2,34x
Nbr of Employees 312
Free-Float 46,8%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 4,66 $
Average target price 17,67 $
Spread / Average Target 279%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Senior Vice President-Research & Development
Joseph S. Camardo Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-76.93%372
GILEAD SCIENCES, INC.-14.14%78 787
REGENERON PHARMACEUTICALS, INC.8.64%74 550
VERTEX PHARMACEUTICALS26.04%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-40.57%28 154